KYMR Q1 2025 Earnings — Kymera Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

KYMRKymera Therapeutics, Inc.

$7B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$22M+114.8% YoY

Gross Profit

$22M100.0% margin

Operating Income

-$74M-336.8% margin

Net Income

-$66M-296.7% margin

EPS (Diluted)

$-0.82

QoQ Revenue Growth

+198.9%

Cash Flow

Operating Cash Flow

-$79M

Free Cash Flow

-$80M

Stock-Based Comp.

$14M

Balance Sheet

Total Assets

$918M

Total Liabilities

$132M

Stockholders' Equity

$786M

Cash & Equivalents

$90M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$22M	$10M	+114.8%
Gross Profit	$22M	$10M	+114.8%
Operating Income	-$74M	-$58M	-28.7%
Net Income	-$66M	-$49M	-35.1%